$RNN Company News Rexahn prices offering at 30%
Post# of 44957
Posted On: 01/13/2014 10:49:40 AM
$RNN Company News
Rexahn prices offering at 30% discount 10:58 a.m. Nov. 29, 2012 - MarketWatch.com
AEterna falls; Inspire, Rexahn rally 2:15 p.m. April 16, 2010 - Val Brickates Kennedy
Javelin rockets, Myriad gains on scrapped merger 12:20 p.m. April 12, 2010 - Val Brickates Kennedy
Wednesday's biggest gaining and declining stocks 3:26 p.m. April 7, 2010 - MarketWatch
Rexahn, Avanir gain; Sequenom falls 12:32 p.m. April 7, 2010 - Val Brickates Kennedy
Letter up 230% last year without trading 3:00 a.m. Jan. 11, 2010 - Peter Brimelow
Morning Market Movers 8:55 a.m. Today - benzinga.com
Why Rexahn Pharmaceuticals (RNN) Is Up Today 10:35 a.m. Jan. 10, 2014 - TheStreet.com
Rexahn up 15% after Buy rating 1:25 p.m. Jan. 9, 2014 - Seeking Alpha
Rexahn's Replacement For Eli Lilly's Gemzar Enters New Clinical Trial 12:20 p.m. Jan. 9, 2014 - Seeking Alpha
Rexahn: A Turn Around Story For 2014 12:49 p.m. Dec. 22, 2013 - Seeking Alpha
Rexahn's Akt-1 Inhibitor To Begin Phase II Trials For Kidney Treatment 1:47 p.m. Nov. 25, 2013 - Seeking Alpha
Rexahn's Recent Clinical Data Points To A New And Better Chemotherapy Pill 7:57 p.m. Oct. 6, 2013 - Seeking Alpha
Rexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel Anti-Cancer Compound RX-3117 6:02 a.m. Sept. 30, 2013 - benzinga.com
Rexahn Regains Rights To Novel Cancer Drug As Teva Continues Its Pipeline Stumble 4:06 p.m. Sept. 5, 2013 - Seeking Alpha
Teva-Rexahn Deal Terminated - Analyst Blog 10:40 a.m. Aug. 30, 2013 - Zacks.com
10-Q: REXAHN PHARMACEUTICALS, INC. 3:15 p.m. Aug. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of SupinoxinTM (RX-5902) a Candidate for Treating Solid Cancer Tumors 6:01 a.m. Aug. 7, 2013 - benzinga.com
Rexahn's CEO Uses A Business-Driven Cancer Model For Shareholder Value 5:34 p.m. Aug. 5, 2013 - Seeking Alpha
Rexahn Redesigns Cancer Superdrug Taxotere 12:58 p.m. July 18, 2013 - Seeking Alpha
Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform 6:05 a.m. July 17, 2013 - benzinga.com
Rexahn Pharmaceuticals Announce IND Submission for RX-3117 6:05 a.m. July 15, 2013 - benzinga.com
Rexahn Pharma Wins US Patent for Novel Anti-Cancer Compounds 6:06 a.m. June 17, 2013 - benzinga.com
Rexahn's Oncology Platform Led By Its Akt-1 Inhibitor Challenges Big Pharma With Ground-Breaking Cancer Therapy 4:53 a.m. June 5, 2013 - Seeking Alpha
10-Q: REXAHN PHARMACEUTICALS, INC. 3:15 p.m. May 9, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K: REXAHN PHARMACEUTICALS, INC. 3:17 p.m. March 22, 2013 - Edgar Online - (EDG = 10Q, 10K)
Rexahn Initiates Phase Ib Clinical Trial of RX-3117 for Treatment of Solid Tumors 8:00 a.m. Jan. 8, 2014 - BusinessWire
Rexahn Pharmaceuticals to Present at the Biotech Showcase 2014 8:00 a.m. Jan. 7, 2014 - BusinessWire
Rexahn Receives Method Patent for Treatment of Solid Tumor Cancers for Supinoxin (TM) (RX-5902) 8:17 a.m. Dec. 11, 2013 - BusinessWire
Rexahn Pharmaceuticals to Participate in Brean Capital 2013 Life Sciences Summit 8:00 a.m. Nov. 19, 2013 - BusinessWire
Rexahn Pharmaceuticals Reports Third Quarter Financial Results and Pipeline Update 8:00 a.m. Nov. 14, 2013 - BusinessWire
Rexahn Announces $5.3 Million At Market Registered Direct Offering 8:00 a.m. Oct. 11, 2013 - BusinessWire
Rexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform from Ohio State University 7:00 a.m. Oct. 10, 2013 - BusinessWire
Rexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel Anti-Cancer Compound RX-3117 7:00 a.m. Sept. 30, 2013 - BusinessWire
Rexahn Awarded Patent in Europe for Cancer Drug Archexin(R) 7:00 a.m. Sept. 12, 2013 - BusinessWire
Rexahn Pharmaceuticals to Present at the 15th Annual Rodman & Renshaw Global Investment Conference on September 9, 2013 7:00 a.m. Sept. 5, 2013 - BusinessWire
Rexahn Pharmaceuticals Provides a Clinical Development and Financial Update 7:00 a.m. Sept. 4, 2013 - BusinessWire
Rexahn Pharmaceuticals Announces Teva will not Exercise its Option to License RX-3117 8:00 a.m. Aug. 28, 2013 - BusinessWire
Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of Supinoxin(TM) (RX-5902) a Candidate for Treating Solid Cancer Tumors 7:00 a.m. Aug. 7, 2013 - BusinessWire
University Of Maryland, Baltimore's Licensing Deals Fuel Local Life Sciences Community 7:30 a.m. Aug. 6, 2013 - PR Newswire
Rexahn Pharmaceuticals Announces $5.7 Million Registered Direct Offering 8:00 a.m. July 24, 2013 - BusinessWire
Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform 7:00 a.m. July 17, 2013 - BusinessWire
Rexahn Pharmaceuticals Announce IND Submission for RX-3117 7:00 a.m. July 15, 2013 - BusinessWire
Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Anti-cancer Isoquinolinamine Compounds 7:00 a.m. July 9, 2013 - BusinessWire
Rexahn Awarded U.S. Patent for Novel Anti-Cancer Compounds 7:00 a.m. June 17, 2013 - BusinessWire
Rexahn Pharmaceuticals To Present At The Second Annual Marcum LLP MicroCap Conference 7:00 a.m. May 20, 2013 - PR Newswire
Rexahn prices offering at 30% discount 10:58 a.m. Nov. 29, 2012 - MarketWatch.com
AEterna falls; Inspire, Rexahn rally 2:15 p.m. April 16, 2010 - Val Brickates Kennedy
Javelin rockets, Myriad gains on scrapped merger 12:20 p.m. April 12, 2010 - Val Brickates Kennedy
Wednesday's biggest gaining and declining stocks 3:26 p.m. April 7, 2010 - MarketWatch
Rexahn, Avanir gain; Sequenom falls 12:32 p.m. April 7, 2010 - Val Brickates Kennedy
Letter up 230% last year without trading 3:00 a.m. Jan. 11, 2010 - Peter Brimelow
Morning Market Movers 8:55 a.m. Today - benzinga.com
Why Rexahn Pharmaceuticals (RNN) Is Up Today 10:35 a.m. Jan. 10, 2014 - TheStreet.com
Rexahn up 15% after Buy rating 1:25 p.m. Jan. 9, 2014 - Seeking Alpha
Rexahn's Replacement For Eli Lilly's Gemzar Enters New Clinical Trial 12:20 p.m. Jan. 9, 2014 - Seeking Alpha
Rexahn: A Turn Around Story For 2014 12:49 p.m. Dec. 22, 2013 - Seeking Alpha
Rexahn's Akt-1 Inhibitor To Begin Phase II Trials For Kidney Treatment 1:47 p.m. Nov. 25, 2013 - Seeking Alpha
Rexahn's Recent Clinical Data Points To A New And Better Chemotherapy Pill 7:57 p.m. Oct. 6, 2013 - Seeking Alpha
Rexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel Anti-Cancer Compound RX-3117 6:02 a.m. Sept. 30, 2013 - benzinga.com
Rexahn Regains Rights To Novel Cancer Drug As Teva Continues Its Pipeline Stumble 4:06 p.m. Sept. 5, 2013 - Seeking Alpha
Teva-Rexahn Deal Terminated - Analyst Blog 10:40 a.m. Aug. 30, 2013 - Zacks.com
10-Q: REXAHN PHARMACEUTICALS, INC. 3:15 p.m. Aug. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of SupinoxinTM (RX-5902) a Candidate for Treating Solid Cancer Tumors 6:01 a.m. Aug. 7, 2013 - benzinga.com
Rexahn's CEO Uses A Business-Driven Cancer Model For Shareholder Value 5:34 p.m. Aug. 5, 2013 - Seeking Alpha
Rexahn Redesigns Cancer Superdrug Taxotere 12:58 p.m. July 18, 2013 - Seeking Alpha
Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform 6:05 a.m. July 17, 2013 - benzinga.com
Rexahn Pharmaceuticals Announce IND Submission for RX-3117 6:05 a.m. July 15, 2013 - benzinga.com
Rexahn Pharma Wins US Patent for Novel Anti-Cancer Compounds 6:06 a.m. June 17, 2013 - benzinga.com
Rexahn's Oncology Platform Led By Its Akt-1 Inhibitor Challenges Big Pharma With Ground-Breaking Cancer Therapy 4:53 a.m. June 5, 2013 - Seeking Alpha
10-Q: REXAHN PHARMACEUTICALS, INC. 3:15 p.m. May 9, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K: REXAHN PHARMACEUTICALS, INC. 3:17 p.m. March 22, 2013 - Edgar Online - (EDG = 10Q, 10K)
Rexahn Initiates Phase Ib Clinical Trial of RX-3117 for Treatment of Solid Tumors 8:00 a.m. Jan. 8, 2014 - BusinessWire
Rexahn Pharmaceuticals to Present at the Biotech Showcase 2014 8:00 a.m. Jan. 7, 2014 - BusinessWire
Rexahn Receives Method Patent for Treatment of Solid Tumor Cancers for Supinoxin (TM) (RX-5902) 8:17 a.m. Dec. 11, 2013 - BusinessWire
Rexahn Pharmaceuticals to Participate in Brean Capital 2013 Life Sciences Summit 8:00 a.m. Nov. 19, 2013 - BusinessWire
Rexahn Pharmaceuticals Reports Third Quarter Financial Results and Pipeline Update 8:00 a.m. Nov. 14, 2013 - BusinessWire
Rexahn Announces $5.3 Million At Market Registered Direct Offering 8:00 a.m. Oct. 11, 2013 - BusinessWire
Rexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform from Ohio State University 7:00 a.m. Oct. 10, 2013 - BusinessWire
Rexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel Anti-Cancer Compound RX-3117 7:00 a.m. Sept. 30, 2013 - BusinessWire
Rexahn Awarded Patent in Europe for Cancer Drug Archexin(R) 7:00 a.m. Sept. 12, 2013 - BusinessWire
Rexahn Pharmaceuticals to Present at the 15th Annual Rodman & Renshaw Global Investment Conference on September 9, 2013 7:00 a.m. Sept. 5, 2013 - BusinessWire
Rexahn Pharmaceuticals Provides a Clinical Development and Financial Update 7:00 a.m. Sept. 4, 2013 - BusinessWire
Rexahn Pharmaceuticals Announces Teva will not Exercise its Option to License RX-3117 8:00 a.m. Aug. 28, 2013 - BusinessWire
Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of Supinoxin(TM) (RX-5902) a Candidate for Treating Solid Cancer Tumors 7:00 a.m. Aug. 7, 2013 - BusinessWire
University Of Maryland, Baltimore's Licensing Deals Fuel Local Life Sciences Community 7:30 a.m. Aug. 6, 2013 - PR Newswire
Rexahn Pharmaceuticals Announces $5.7 Million Registered Direct Offering 8:00 a.m. July 24, 2013 - BusinessWire
Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform 7:00 a.m. July 17, 2013 - BusinessWire
Rexahn Pharmaceuticals Announce IND Submission for RX-3117 7:00 a.m. July 15, 2013 - BusinessWire
Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Anti-cancer Isoquinolinamine Compounds 7:00 a.m. July 9, 2013 - BusinessWire
Rexahn Awarded U.S. Patent for Novel Anti-Cancer Compounds 7:00 a.m. June 17, 2013 - BusinessWire
Rexahn Pharmaceuticals To Present At The Second Annual Marcum LLP MicroCap Conference 7:00 a.m. May 20, 2013 - PR Newswire
(0)
(0)